Effectiveness and Safety of Zotarolimus-Eluting Stent (Resolute™ Integrity) in Patients with Diffuse Long Coronary Artery Disease
- Author:
Keun Ho PARK
1
;
Youngkeun AHN
;
Young Youp KOH
;
Young Jae KI
;
Sung Soo KIM
;
Hyun Kuk KIM
;
Dong Hyun CHOI
;
Young Joon HONG
;
Jin Yong HWANG
;
Do Hoi KIM
;
Jay Young RHEW
;
Jae Kean RYU
;
Jong Seon PARK
;
Tae Ho PARK
;
Tae Hyun YANG
;
Seok Kyu OH
;
Bong Ryeol LEE
;
Seung Uk LEE
;
Sang Gon LEE
;
Kook Jin CHUN
;
Jang Hyun CHO
;
Kwang Soo CHA
;
Jei Keon CHAE
;
Seung Ho HUR
;
Sun Ho HWANG
;
Hun Sik PARK
;
Doo Il KIM
Author Information
- Publication Type:Original Article
- Keywords: Drug-eluting stents; Coronary artery disease; Treatment outcome
- MeSH: Coronary Artery Disease; Coronary Vessels; Death; Drug-Eluting Stents; Follow-Up Studies; Heart Failure; Humans; Hypertension; Incidence; Korea; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Stents; Thrombosis; Treatment Outcome
- From:Korean Circulation Journal 2019;49(8):709-720
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND OBJECTIVES: Diffuse long coronary artery disease (DLCAD) still has unfavorable clinical outcomes after successful percutaneous coronary intervention (PCI). Therefore, we aimed to evaluate the effectiveness and safety of Resolute™ zotarolimus-eluting stent (R-ZES; Resolute™ Integrity) for patients with DLCAD. METHODS: From December 2011 to December 2014, 1,011 patients who underwent PCI using R-ZES for CAD with longer than 25 mm lesion were prospectively enrolled from 21 hospitals in Korea. We assessed the clinical outcome of major adverse cardiac events (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinically-driven target vessel revascularization at 12 months. RESULTS: Mean age was 63.8±10.8 years, 701 (69.3%) patients were male, 572 (87.0%) patients had hypertension, 339 (33.8%) patients had diabetes, 549 (54.3%) patients diagnosed with acute MI and 545 (53.9%) patients had multi-vessel disease (MVD). A total of 1,697 stents were implanted into a total of 1,472 lesions. The mean diameter was 3.07±0.38 mm and the length was 28.27±6.97 mm. Multiple overlapping stents were performed in 205 (13.8%) lesions. A 12-month clinical follow-up was available in 1,004 patients (99.3%). The incidences of MACE and definite stent thrombosis at 12-month were 3.0% and 0.3% respectively. On multivariate Cox-regression analysis, multiple overlapping stents implantation, previous congestive heart failure, MVD, and age ≥75 years were independent predictors of one-year MACE. CONCLUSIONS: Our study shows that R-ZES has an excellent 1-year clinical outcome in Korean patients with DLCAD.
